Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

9.710 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
33 Stocks Moving In Friday's Mid-Day Session ↗
Gainers TD Holdings, Inc. (NASDAQ: GLG) jumped 49% to $1.21 after the company entered a non-binding letter of intent to acquire Guangdong Jinbochuang Special Purpose Vehicle Co.... 
Via Benzinga
News headline image
Analyzing FibroGen's Unusual Options Activity ↗
Shares of FibroGen (NASDAQ:FGEN) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $13.83. Sentiment: BEARISH Option... 
Via Benzinga
News headline image
FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall ↗
FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. 
Via InvestorPlace
News headline image
Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views ↗
Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% to 4,346.93. The U.S.... 
Via Benzinga
Topics Earnings Stocks
News headline image
Why FibroGen's Stock Is Getting Hammered Today ↗
FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to... 
Via Benzinga
News headline image
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment ↗
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021 ↗
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE: 
Via Benzinga
News headline image
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies ↗
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Friday ↗
Credit Suisse raised Cintas Corporation (NASDAQ: CTAS) price target from $350 to $375. Cintas shares rose 1.4% to $374.12 in pre-market trading. Barclays raised the price target... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
Via Benzinga
News headline image
22 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Aehr Test Systems (NASDAQ: AEHR) shares rose 25.3% to $3.52 in pre-market trading after the company reported better-than-expected Q4 results and issued strong FY22 sales... 
Via Benzinga
News headline image
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall? ↗
FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday the... 
Via Benzinga
News headline image
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict ↗
FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday w... 
Via Benzinga
News headline image
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions ↗
Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
News headline image
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
News headline image
14 Biotech Stocks To Watch Over The Next 6 Months ↗
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings ↗
FibroGen Inc (NASDAQ: FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space.... 
Via Benzinga
News headline image
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FIBROGEN CLASS ACTION REMINDER
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
FIBROGEN SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FGEN Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 11, 2021 Deadline in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
FRIDAY DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
FIBROGEN SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.